PubMed

Shifting the disease management paradigm from glucose: what are the cons?

Hanefeld M, Bornstein SR, Pistrosch F.

Diabetes Care. 2009 Nov;32 Suppl 2:S353-6. No abstract available. PMID: 19875580 [PubMed - in process]Related articles

Differences in the results and interpretation of oxidized LDL cholesterol by two ELISA assays--an evaluation with samples from the PIOstat study.

Pfützner A, Efstrathios K, Löbig M, Armbruster FP, Hanefeld M, Forst T.

Clin Lab. 2009;55(7-8):275-81.PMID: 19894406 [PubMed - in process]Related articles

Identification of the UBP1 locus as a critical blood pressure determinant using a combination of mouse and human genetics.

Koutnikova H, Laakso M, Lu L, Combe R, Paananen J, Kuulasmaa T, Kuusisto J, Häring HU, Hansen T, Pedersen O, Smith U, Hanefeld M, Williams RW, Auwerx J.

PLoS Genet. 2009 Aug;5(8):e1000591. Epub 2009 Aug 7.PMID: 19662162 [PubMed - indexed for MEDLINE]Related articlesFree article

The role of pioglitazone in modifying the atherogenic lipoprotein profile.

Hanefeld M.

Diabetes Obes Metab. 2009 Aug;11(8):742-56. Epub 2009 Jun 10.PMID: 19519869 [PubMed - in process]Related articles

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Team.

Lancet. 2009 Jun 20;373(9681):2125-35. Epub 2009 Jun 6.PMID: 19501900 [PubMed - indexed for MEDLINE]Related articles

The "glucose pentagon": assessing glycemic control of patients with diabetes mellitus by a model integrating different parameters from glucose profiles.

Thomas A, Schönauer M, Achermann F, Schnell O, Hanefeld M, Ziegelasch HJ, Mastrototaro J, Heinemann L.

Diabetes Technol Ther. 2009 Jun;11(6):399-409.PMID: 19459770 [PubMed - indexed for MEDLINE]Related articles

Pulse pressure is a strong predictor of cardiovascular risk: Data of the risk factors in impaired glucose tolerance for atherosclerosis and diabetes and the Sofia Metabolic Syndrome studies.

Temelkova-Kurktschiev TS, Kurktschiev DP, Vladimirova-Kitova LG, Koehler C, Henkel E, Todorova BR, Schaper F, Fuecker K, Hanefeld M.

Folia Med (Plovdiv). 2009 Jan-Mar;51(1):34-41.PMID: 19437896 [PubMed - indexed for MEDLINE]Related articles

[Challenge in diabetes therapy: effects of glitazones beyond blood glucose control]

Schernthaner G, Forst T, Gulba D, Haberbosch W, Hanefeld M, Linss G, März W, Mehnert H, Rosak C, Schnell O, Seufert J, Tschöpe D, Erdmann E.

Dtsch Med Wochenschr. 2009 Apr;134(18):949-54. Epub 2009 Apr 21. Review. German. PMID: 19384816 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study.

Ansquer JC, Bekaert I, Guy M, Hanefeld M, Simon A; Study Investigators.

Am J Cardiovasc Drugs. 2009;9(2):91-101. doi: 10.2165/00129784-200909020-00003.PMID: 19331437 [PubMed - indexed for MEDLINE]Related articles

Changes in insulin resistance and cardiovascular risk induced by PPARgamma activation have no impact on RBP4 plasma concentrations in nondiabetic patients.

Pfützner A, Schöndorf T, Hanefeld M, Lübben G, Kann PH, Karagiannis E, Wilhelm B, Forst T.

Horm Metab Res. 2009 Mar;41(3):202-6. Epub 2009 Feb 17.PMID: 19224430 [PubMed - indexed for MEDLINE]Related articles

Effect of acarbose on postmeal mononuclear blood cell response in patients with early type 2 diabetes: the AI(I)DA study.

Hanefeld M, Schaper F, Koehler C, Bergmann S, Ugocsai P, Stelzer J, Schmitz G.

Horm Metab Res. 2009 Feb;41(2):132-6. Epub 2009 Feb 12.PMID: 19214923 [PubMed - indexed for MEDLINE]Related articles

The future of the metabolic syndrome.

Schwarz PE, Bornstein SR, Hanefeld M.

Horm Metab Res. 2009 Feb;41(2):73-4. Epub 2009 Feb 12. No abstract available. PMID: 19214919 [PubMed - indexed for MEDLINE]Related articles

["Diabetes in Germany"(DIG) study. A prospective 4-year-follow-up study on the quality of treatment for type 2 diabetes in daily practice]

Ott P, Benke I, Stelzer J, Köhler C, Hanefeld M.

Dtsch Med Wochenschr. 2009 Feb;134(7):291-7. Epub 2009 Feb 5. German. PMID: 19197810 [PubMed - indexed for MEDLINE]Related articles

[Interpretation of oral glucose tolerance tests]

Hanefeld M, Köhler C.

Dtsch Med Wochenschr. 2009 Feb;134(6):266. Epub 2009 Jan 29. German. No abstract available. PMID: 19180421 [PubMed - indexed for MEDLINE]Related articles

An update on preventive and regenerative therapies in diabetes mellitus.

Reimann M, Bonifacio E, Solimena M, Schwarz PE, Ludwig B, Hanefeld M, Bornstein SR.

Pharmacol Ther. 2009 Mar;121(3):317-31. Epub 2008 Dec 25. Review.PMID: 19168093 [PubMed - indexed for MEDLINE]Related articles

Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial.

Hanefeld M, Karasik A, Koehler C, Westermeier T, Chiasson JL.

Diab Vasc Dis Res. 2009 Jan;6(1):32-7.PMID: 19156626 [PubMed - indexed for MEDLINE]Related articles

The Finnish Diabetes Risk Score is associated with insulin resistance and progression towards type 2 diabetes.

Schwarz PE, Li J, Reimann M, Schutte AE, Bergmann A, Hanefeld M, Bornstein SR, Schulze J, Tuomilehto J, Lindström J.

J Clin Endocrinol Metab. 2009 Mar;94(3):920-6. Epub 2008 Dec 23.PMID: 19106274 [PubMed - indexed for MEDLINE]Related articles

Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes.

Pistrosch F, Schaper F, Passauer J, Koehler C, Bornstein SR, Hanefeld M.

Horm Metab Res. 2009 Feb;41(2):104-8. Epub 2008 Dec 5.PMID: 19061152 [PubMed - indexed for MEDLINE]Related articles

Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk.

Forst T, Wilhelm B, Pfützner A, Fuchs W, Lehmann U, Schaper F, Weber M, Müller J, Konrad T, Hanefeld M.

Diab Vasc Dis Res. 2008 Nov;5(4):298-303.PMID: 18958840 [PubMed - indexed for MEDLINE]Related articles

Polymorphisms in perilipin gene (PLIN) are not associated with obesity and weight variation in people with high risk of type 2 diabetes.

Bergmann A, Li J, Reimann M, Hentrich T, Hanefeld M, Bornstein SR, Schwarz PE.

Exp Clin Endocrinol Diabetes. 2008 Sep;116 Suppl 1:S56-8. Epub 2008 Sep 5.PMID: 18777456 [PubMed - indexed for MEDLINE]Related articles

The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.

Mohler ER 3rd, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, Zalewski A; Darapladib Investigators.

J Am Coll Cardiol. 2008 Apr 29;51(17):1632-41.PMID: 18436114 [PubMed - indexed for MEDLINE]Related articles

Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study).

Komajda M, Curtis P, Hanefeld M, Beck-Nielsen H, Pocock SJ, Zambanini A, Jones NP, Gomis R, Home PD; RECORD Study Group.

Cardiovasc Diabetol. 2008 Apr 24;7:10.PMID: 18435852 [PubMed - indexed for MEDLINE]Related articlesFree article

[Controlled studies in German language publications]

Hanefeld M.

Dtsch Med Wochenschr. 2008 Apr;133(15):795. German. No abstract available. PMID: 18382958 [PubMed - indexed for MEDLINE]Related articles

Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT study.

Leonhardt W, Pfützner A, Müller J, Pietzsch J, Forst T, Karagiannis E, Lübben G, Hanefeld M.

Atherosclerosis. 2008 Nov;201(1):155-62. Epub 2008 Apr 18.PMID: 18374336 [PubMed - in process]Related articles

Evaluation of a diabetes management system based on practice guidelines, integrated care, and continuous quality management in a Federal State of Germany: a population-based approach to health care research.

Rothe U, Müller G, Schwarz PE, Seifert M, Kunath H, Koch R, Bergmann S, Julius U, Bornstein SR, Hanefeld M, Schulze J.

Diabetes Care. 2008 May;31(5):863-8. Epub 2008 Mar 10.PMID: 18332161 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of acarbose on vascular disease in patients with abnormal glucose tolerance.

Hanefeld M, Schaper F, Koehler C.

Cardiovasc Drugs Ther. 2008 Jun;22(3):225-31. Epub 2008 Feb 29. Review.PMID: 18309462 [PubMed - indexed for MEDLINE]Related articles

Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia.

Milicevic Z, Raz I, Beattie SD, Campaigne BN, Sarwat S, Gromniak E, Kowalska I, Galic E, Tan M, Hanefeld M.

Diabetes Care. 2008 Feb;31 Suppl 2:S155-60. Review.PMID: 18227478 [PubMed - indexed for MEDLINE]Related articlesFree article

Acarbose: oral anti-diabetes drug with additional cardiovascular benefits.

Hanefeld M, Schaper F.

Expert Rev Cardiovasc Ther. 2008 Feb;6(2):153-63. Review. Erratum in: Expert Rev Cardiovasc Ther. 2009 Mar;7(3):330. PMID: 18248270 [PubMed - indexed for MEDLINE]Related articles

Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk -- results from the PIOSTAT study.

Pfützner A, Hanefeld M, Lübben G, Weber MM, Karagiannis E, Köhler C, Hohberg C, Forst T.

Horm Metab Res. 2007 Oct;39(10):764-8.PMID: 17952841 [PubMed - indexed for MEDLINE]Related articles

Is rosiglitazone associated with increased risk for cardiovascular events?

Hanefeld M.

Nat Clin Pract Cardiovasc Med. 2007 Dec;4(12):648-9. Epub 2007 Oct 9. No abstract available. PMID: 17925798 [PubMed]Related articles

Comparison of the prevalence of the metabolic syndrome by WHO, AHA/NHLBI, and IDF definitions in a German population with type 2 diabetes: the Diabetes in Germany (DIG) Study.

Koehler C, Ott P, Benke I, Hanefeld M; DIG Study Group.

Horm Metab Res. 2007 Sep;39(9):632-5.PMID: 17846969 [PubMed - indexed for MEDLINE]Related articles

The challenge of the Metabolic Syndrome.

Hanefeld M, Ceriello A, Schwarz PE, Bornstein SR.

Horm Metab Res. 2007 Sep;39(9):625-6. No abstract available. PMID: 17846967 [PubMed - indexed for MEDLINE]Related articles

Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes.

Hanefeld M.

Cardiovasc Diabetol. 2007 Aug 15;6:20. Review.PMID: 17697384 [PubMed - indexed for MEDLINE]Related articlesFree article

Improved metabolic control by Ipomoea batatas (Caiapo) is associated with increased adiponectin and decreased fibrinogen levels in type 2 diabetic subjects.

Ludvik B, Hanefeld M, Pacini G.

Diabetes Obes Metab. 2008 Jul;10(7):586-92. Epub 2007 Jul 21.PMID: 17645559 [PubMed - indexed for MEDLINE]Related articles

Pioglitazone and sulfonylureas: effectively treating type 2 diabetes.

Hanefeld M.

Int J Clin Pract Suppl. 2007 Jun;(153):20-7. Review.PMID: 17594390 [PubMed - indexed for MEDLINE]Related articlesFree article

Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.

Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP; Sitagliptin Study 014 Investigators.

Curr Med Res Opin. 2007 Jun;23(6):1329-39. Epub 2007 Apr 30.PMID: 17559733 [PubMed - indexed for MEDLINE]Related articles

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.

Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Group.

N Engl J Med. 2007 Jul 5;357(1):28-38. Epub 2007 Jun 5.PMID: 17551159 [PubMed - indexed for MEDLINE]Related articlesFree article

Rosiglitazone RECORD study: glucose control outcomes at 18 months.

Home PD, Jones NP, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Komajda M, Curtis P; RECORD Study Group.

Diabet Med. 2007 Jun;24(6):626-34.PMID: 17517066 [PubMed - indexed for MEDLINE]Related articlesFree article

Relationship between diurnal blood pressure variation and diurnal blood glucose levels in type 2 diabetic patients.

Pistrosch F, Reissmann E, Wildbrett J, Koehler C, Hanefeld M.

Am J Hypertens. 2007 May;20(5):541-5.PMID: 17485018 [PubMed - indexed for MEDLINE]Related articles

Glucagon as a determinant of fibrinolytic activity in men with different stages of glucose tolerance: impact of glucagon on fibrinolysis.

Henkel E, Gallo S, Siegert G, Koehler C, Hanefeld M.

Blood Coagul Fibrinolysis. 2007 Jun;18(4):327-34.PMID: 17473573 [PubMed - indexed for MEDLINE]Related articles

Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study.

Hanefeld M, Koehler C, Gallo S, Benke I, Ott P.

Cardiovasc Diabetol. 2007 Apr 26;6:13.PMID: 17462080 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT Study.

Forst T, Pfützner A, Lübben G, Weber M, Marx N, Karagiannis E, Koehler C, Baurecht W, Hohberg C, Hanefeld M.

Metabolism. 2007 Apr;56(4):491-6.PMID: 17379006 [PubMed - indexed for MEDLINE]Related articles

Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study.

Hanefeld M, Marx N, Pfützner A, Baurecht W, Lübben G, Karagiannis E, Stier U, Forst T.

J Am Coll Cardiol. 2007 Jan 23;49(3):290-7. Epub 2007 Jan 8.PMID: 17239709 [PubMed - indexed for MEDLINE]Related articles

[History and definition(s) of metabolic syndrome]

Hanefeld M, Schaper F, Ceriello A.

Internist (Berl). 2007 Feb;48(2):117-25. German. PMID: 17226009 [PubMed - indexed for MEDLINE]Related articles

The effect of glucose variability on the risk of microvascular complications in type 1 diabetes.

Monnier L, Colette C, Leiter L, Ceriello A, Hanefeld M, Owens D, Tajima N, Tuomiletho J, Davidson J; PGR Group.

Diabetes Care. 2007 Jan;30(1):185-6; author reply 187-8. No abstract available. PMID: 17192363 [PubMed - indexed for MEDLINE]Related articlesFree article

A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes.

Hanefeld M, Patwardhan R, Jones NP; Rosiglitazone Clinical Trials Study Group.

Nutr Metab Cardiovasc Dis. 2007 Jan;17(1):13-23. Epub 2006 Mar 20.PMID: 17174222 [PubMed - indexed for MEDLINE]Related articles

[The metabolic syndrome: where are we going and for what benefits?]

Hanefeld M.

Dtsch Med Wochenschr. 2006 Dec;131 Suppl 8:S236-9. Review. German. PMID: 17139577 [PubMed - indexed for MEDLINE]Related articles

Elevated fasting glucose levels predicts IGT and diabetes also in middle-age subjects.

Schwarz PE, Bornstein SR, Hanefeld M.

Diabetes Res Clin Pract. 2007 Jul;77(1):148-50. Epub 2006 Nov 7.PMID: 17092598 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H; Sitagliptin Study 023 Group.

Diabetologia. 2006 Nov;49(11):2564-71. Epub 2006 Sep 26.PMID: 17001471 [PubMed - indexed for MEDLINE]Related articles

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR.

Lancet. 2006 Sep 23;368(9541):1096-105. Erratum in: Lancet. 2006 Nov 18;368(9549):1770. PMID: 16997664 [PubMed - indexed for MEDLINE]Related articles